Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Antibody microarrays: Current status and key technological advances

Wingren, Christer LU and Borrebaeck, Carl LU (2006) In OMICS: A Journal of Integrative Biology 10(3). p.411-427
Abstract
Antibody-based microarrays are among the novel classes of rapidly evolving proteomic technologies that holds great promise in biomedicine. Miniaturized microarrays (< 1 cm(2)) can be printed with thousands of individual antibodies carrying the desired specificities, and with biological sample (e.g., an entire proteome) added, virtually any specifically bound analytes can be detected. While consuming only minute amounts (<mu L scale) of reagents, ultra-sensitive assays (zeptomol range) can readily be performed in a highly multiplexed manner. The microarray patterns generated can then be transformed into proteomic maps, or detailed molecular fingerprints, revealing the composition of the proteome. Thus, protein expression profiling and... (More)
Antibody-based microarrays are among the novel classes of rapidly evolving proteomic technologies that holds great promise in biomedicine. Miniaturized microarrays (< 1 cm(2)) can be printed with thousands of individual antibodies carrying the desired specificities, and with biological sample (e.g., an entire proteome) added, virtually any specifically bound analytes can be detected. While consuming only minute amounts (<mu L scale) of reagents, ultra-sensitive assays (zeptomol range) can readily be performed in a highly multiplexed manner. The microarray patterns generated can then be transformed into proteomic maps, or detailed molecular fingerprints, revealing the composition of the proteome. Thus, protein expression profiling and global proteome analysis using this tool will offer new opportunities for drug target and biomarker discovery, disease diagnostics, and insights into disease biology. Adopting the antibody microarray technology platform, several biomedical applications, ranging from focused assays to proteome-scale analysis will be rapidly emerging in the coming years. This review will discuss the current status of the antibody microarray technology focusing on recent technological advances and key issues in the process of evolving the methodology into a high-performing proteomic research tool. (Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
OMICS: A Journal of Integrative Biology
volume
10
issue
3
pages
411 - 427
publisher
Mary Ann Liebert, Inc.
external identifiers
  • wos:000241666200012
  • scopus:33750959353
ISSN
1557-8100
DOI
10.1089/omi.2006.10.411
language
English
LU publication?
yes
id
d4aebbbf-25f9-4252-a000-9f2deeab611c (old id 378643)
date added to LUP
2016-04-01 11:51:12
date last changed
2021-10-03 04:20:22
@article{d4aebbbf-25f9-4252-a000-9f2deeab611c,
  abstract     = {Antibody-based microarrays are among the novel classes of rapidly evolving proteomic technologies that holds great promise in biomedicine. Miniaturized microarrays (&lt; 1 cm(2)) can be printed with thousands of individual antibodies carrying the desired specificities, and with biological sample (e.g., an entire proteome) added, virtually any specifically bound analytes can be detected. While consuming only minute amounts (&lt;mu L scale) of reagents, ultra-sensitive assays (zeptomol range) can readily be performed in a highly multiplexed manner. The microarray patterns generated can then be transformed into proteomic maps, or detailed molecular fingerprints, revealing the composition of the proteome. Thus, protein expression profiling and global proteome analysis using this tool will offer new opportunities for drug target and biomarker discovery, disease diagnostics, and insights into disease biology. Adopting the antibody microarray technology platform, several biomedical applications, ranging from focused assays to proteome-scale analysis will be rapidly emerging in the coming years. This review will discuss the current status of the antibody microarray technology focusing on recent technological advances and key issues in the process of evolving the methodology into a high-performing proteomic research tool.},
  author       = {Wingren, Christer and Borrebaeck, Carl},
  issn         = {1557-8100},
  language     = {eng},
  number       = {3},
  pages        = {411--427},
  publisher    = {Mary Ann Liebert, Inc.},
  series       = {OMICS: A Journal of Integrative Biology},
  title        = {Antibody microarrays: Current status and key technological advances},
  url          = {http://dx.doi.org/10.1089/omi.2006.10.411},
  doi          = {10.1089/omi.2006.10.411},
  volume       = {10},
  year         = {2006},
}